GE HealthCare Technologies Inc. (GEHC)

FY2025 revenue grew ~5% organically to ~$20B. This is roughly in line with Siemens Healthineers but well below medtech growth leaders like Intuitive Surgical or Stryker. The imaging equipment market grows 4-6% annually, and GEHC is growing at market pace rather than taking meaningful share.

GEHC is #1 or #2 in most imaging modalities (MRI, CT, ultrasound) globally. Share positions are stable but not expanding. In China — a critical growth market — GEHC faces increasing pressure from domestic competitors (United Imaging, Mindray) that offer competitive quality at lower prices.

Large imaging equipment is a considered purchase for hospitals — procurement involves multi-month evaluations and competitive bidding. GEHC can command premium pricing for its flagship systems but faces intense competition from Siemens and increasingly from Chinese manufacturers in value segments. Service contract pricing is stickier.

GEHC has received 130+ FDA-cleared AI algorithms — more than most competitors. The SIGNA Champion MRI and Revolution Apex CT are competitive new platforms. However, the cadence of truly differentiated product launches has been slower than Siemens Healthineers, which has been more innovative in photon-counting CT and advanced imaging.

Hospitals standardize on a single imaging vendor for workflow consistency, training, and integration with PACS/RIS systems. Switching from GE to Siemens imaging requires retraining radiologists and technologists, restructuring IT integrations, and disrupting clinical workflows. Service contracts typically run 5-10 years.

GEHC's Edison AI platform benefits from data network effects — more imaging data improves AI algorithm accuracy. The installed base of 4M+ devices globally generates significant data. However, regulatory constraints on health data sharing limit the speed of this flywheel. Network effects are real but slow-moving.

FDA 510(k) and CE mark approvals for medical devices create meaningful barriers. GEHC has thousands of patents covering imaging technology, AI algorithms, and contrast agents. The pharmaceutical diagnostics business (Omnipaque, Visipaque) has additional drug regulatory barriers. Regulatory complexity is a moat for incumbents.

Medical imaging R&D is expensive ($1.5B+ annually for GEHC) and requires deep physics, engineering, and clinical expertise. However, Chinese competitors are demonstrating that adequate imaging quality can be achieved at lower R&D cost, challenging the assumption that capital intensity is a durable barrier.

FY2026 EPS estimates have been revised up ~6% as margin expansion programs deliver ahead of schedule. The Street models 10-12% EPS growth primarily from operational improvement rather than revenue acceleration. Beats have been consistent but modest.

The AI-in-healthcare narrative is a tailwind for GEHC's positioning. The post-spinoff 'new company, new culture' story resonates. However, periodic headlines about Chinese competitors gaining ground in emerging markets and US hospital capital spending softness create concern.

CEO Peter Arduini is executing a credible margin improvement plan, targeting 20%+ EBIT margins by 2028. The lean transformation is driving results. Capital allocation is balanced between R&D investment, debt reduction, and share buybacks. The strategy is sound but early innings — GEHC needs 2-3 more years to prove out the full transformation.